Can Pan-Immune inflammation value and systemic inflammatory response index be used clinically to predict inflammation in patients with non-small cell lung cancer
| dc.authorid | 0000-0001-9274-6237 | |
| dc.authorid | 0000-0003-0786-5077 | |
| dc.authorid | 0000-0003-0839-8191 | |
| dc.contributor.author | Karaoğlanoğlu, Selen | |
| dc.contributor.author | Erdal, Hüseyin | |
| dc.contributor.author | Sönmez, Müge | |
| dc.date.accessioned | 2024-07-29T13:05:37Z | |
| dc.date.available | 2024-07-29T13:05:37Z | |
| dc.date.issued | 2024 | |
| dc.department | Tıp Fakültesi | |
| dc.description.abstract | Lung cancer is one of the most cancer type with the highest rate of cancer-related deaths in worldwide. Chronic inflammation has been associated with many diseases, including cancer, and the immune inflammatory re- sponse plays an important role in cancer patients. The aim of the study is to investigate the role of whether the pan- immune-inflammation value (PIV) and the systemic inflammatory response index (SIRI) are effective in predicting non- small lung cancer patients. Methods: In this retrospective case-control study, eighty-four patients and 71 healthy controls followed in Ordu State Hospital, Department of Medical Oncology from January 2020- to January 2023 were included. Results: White Blood Cell, Neutrophil, Hemoglobin , RDW, CRP were statistically significant between the study groups (p<0.05). A statistically significant difference was found between SII, SIRI, PIV, NLR, LMR and dNLR indices between the case and healthy subjects (p<0.05). However, there was no significant difference in PLR levels between the groups (p>0.05). Conclusion: We indicated that SIRI and PIV could be novel cost-effective biomarkers and treatment response precur- sors in patients with NSCLC. | |
| dc.identifier.doi | 10.14744/ejmi.2023.39651 | |
| dc.identifier.endpage | 57 | en_US |
| dc.identifier.issn | 2602-3164 | |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 54 | en_US |
| dc.identifier.uri | https:/dx.doi.org/ 10.14744/ejmi.2023.39651 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12451/12262 | |
| dc.identifier.volume | 8 | en_US |
| dc.indekslendigikaynak | TR-Dizin | |
| dc.language.iso | en | |
| dc.publisher | Kare Yayıncılık | |
| dc.relation.ispartof | Eurasian Journal of Medical Investigation | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/embargoedAccess | |
| dc.subject | Non-small Cell Lung Cancer | |
| dc.subject | Inflammation | |
| dc.subject | Systemic Inflammatory Response Index | |
| dc.subject | Pan-immune-inflammation Value | |
| dc.title | Can Pan-Immune inflammation value and systemic inflammatory response index be used clinically to predict inflammation in patients with non-small cell lung cancer | |
| dc.type | Article |
